LTR Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. The company is headquartered in Brisbane, Queensland. The company went IPO on 2023-12-11. The firm is developing and commercializing therapies that address significant unmet medical needs. The firm is focused on improving men’s health through clinical development and commercialization of nasal spray treatments for erectile dysfunction. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. The firm is also advancing OROFLOW, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) - a debilitating group of conditions affecting swallowing function. The firm's subsidiary is LTR Pharma Inc.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción LTPLF?
El precio actual de LTPLF es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de LTR Pharma Ltd?
LTR Pharma Ltd pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de LTR Pharma Ltd?
La capitalización bursátil actual de LTR Pharma Ltd es $NaN
